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The tumor, node, metastasis system for cancer staging evolved in the
middle of the last century. It was adopted for the staging of lung
cancer by the American Joint Committee on Cancer in 1973 and
used by the Union Internationale Contre le Cancer (UICC) in 1974
for its second edition of the Classification of Malignant Disease.
Subsequent revisions of the international tumor, node, metastasis
staging system in lung cancer, up to and including the fifth revision
enacted in January 1997, were largely based on Dr. Clifton Moun-
tain’s database in Houston. The International Association for the
Study of Lung Cancer established its International Staging Commit-
tee in 1997 to collect data on lung cancer cases from around the
world treated by all modalities. This project has now collected over
100,000 cases and has been accepted as the primary source of
recommendations by the UICC for the next revision of the Interna-
tional Staging System for Lung Cancer due to be enacted in January
of 2009. This article describes the achievements of this project and
the present state of the database. The authors set out the steps that
are necessary before the International Association for the Study of
Lung Cancer is able to submit its recommendations to the UICC at
the end of 2006. Subject to editorial review, these recommendations
will be disseminated to the lung cancer community through a series
of publications in this Journal. This article will set the scene for
these subsequent publications and, possibly, will garner support and
ideas for the next phase of this long-term project.
(J Thorac Oncol. 2006;1: 281–286)
The tumor, node, metastasis (TNM) concept for cancerstaging was developed by Pierre Denoix between 1943
and 1952.1,2 In 1953, the Union Internationale Contre le
Cancer (UICC) Committee on Tumor Nomenclature and
Statistics accepted this as the basis for the classification of the
anatomical extent of disease.3 In 1968, it was incorporated in
the first edition of the UICC manual, TNM Classification of
Malignant Tumours.
In 1973, the American Joint Committee on Cancer Task
Force on Lung Cancer proposed a system for the clinical
staging of lung cancer, using TNM, based on 2155 cases in
the database of Dr. Clifton Mountain at M. D. Anderson
Cancer Center in Houston.4 In 1974, the UICC in its second
edition of the TNM Classification of Malignant Tumours
accepted these proposals for lung cancer, ensuring uniformity
between the two staging manuals.
This relationship underpinned every revision since, up
to and including the fifth revision enacted in 1997.5 By this
time Dr. Mountain’s database had grown to 5319 cases,
including 4351 consecutive patients treated at M. D. Ander-
son and 968 cases in which data had been sent to M. D.
Anderson for confirmation of stage and histology.
At a workshop on intrathoracic staging held in London
in 1996 and sponsored by the International Association for
the Study of Lung Cancer (IASLC), the proposal for the fifth
revision was presented by Dr. Mountain. After further dis-
cussion, it was felt that there was a need and opportunity to
develop an international database, to continue this important
work and to inform future revisions of the TNM Classification
of Malignant Tumours on lung cancer.6 It was felt that the
IASLC was uniquely placed to take on this work, as it was the
only global organization dedicated to the study of lung
cancer, and its membership included representatives from all
disciplines involved in lung cancer care. The board of the
IASLC agreed to this proposal in December of 1998 and
allocated pump-priming funds. A committee was formed with
appropriate geographical and specialist representation. It was
agreed that such a database must include lung cancer cases
treated by all modalities, including supportive care and mul-
timodality treatment, and that the committee should strive to
ensure that any recommendations emanating from the data-
base would be relevant to all disciplines worldwide.
At its first meetings, in London in June of 1999 and
February of 2000, and in Tokyo during the Ninth World
Conference on Lung Cancer in August of 2000, the commit-
tee identified key stakeholders and enlisted their support,
agreed on a timetable, and established an outline budget. The
constraints of time and funding mandated that a retrospective
database be established first, pooling data from established
databases from around the world. With an unrestricted edu-
cational grant from Eli Lilly and Company a further meeting
was held in London in February of 2001. Representatives
from 23 institutions in 12 countries attended, presented data
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on over 80,000 cases held in their databases, and gave
provisional support for an international database. At that
meeting, it was hoped that the project could recruit 30,000
suitable cases in time to inform the next revision. At that
time, the UICC intended the seventh revision to be enacted in
January of 2007, requiring the IASLC to submit its recom-
mendations by January of 2005. It was decided that the
database should only collect cases treated between 1990 and
1998 so that data on 5-year survival could be collected in time
for this deadline. Our partner in the pharmaceutical industry
generously continued support for this project, underwriting
the whole of the projected budget for a 5-year period. With
funding secure, the database was founded in cooperation with
Cancer Research and Biostatistics (CRAB), an established
center in Seattle with expertise in the collection and collation
of data in collaborative, multicenter, studies in North Amer-
ica. A draft of the data elements and data dictionary was
developed in 2001, reviewed at another meeting of the com-
mittee in April of 2002, and finalized in October of 2002.
Data use agreements between each institution and CRAB,
acting for the committee, were then developed and executed.
The data elements are listed in Appendix 2.
At the 10th World Conference on Lung Cancer in
Vancouver in August of 2003, data were presented on 25,902
cases. It was decided to seek participation from more centers.
Also at this time, it was announced that the UICC has revised
its program for the seventh revision. The deadline for sub-
mission from the IASLC project was extended to January of
2007 so that the UICC review process could be completed in
time for the seventh revision to be enacted in January of
2009. This means that final recommendations from the com-
mittee now need to be submitted to the IASLC Board by the
fall of 2006. The upper time limit for included cases was
extended from 1998 to 2000 in light of this new timeline.
At a committee meeting in Seattle in June of 2004, data
on 50,454 cases were presented. A decision to close the
database to additional cases as of April 1, 2005, was reached
(although some were allowed in later to address specific
issues). By the 11th World Conference in Barcelona, 99,794
cases had been accrued to the database. At that meeting,
subcommittees were established to focus on issues regarding
the extent of the tumor, the status of involved nodes, and (as
a later addition) the extent of distant disease. These subcom-
mittees were charged with using the database to revise the
TNM system and then to redefine the clinical and pathologic
staging systems for non-small cell lung cancer. Further sub-
committees were added to establish an international nodal
chart, to study the issue of additional tumor nodules, to assess
the relevance of TNM staging in small cell lung cancer, to
explore prognostic factors beyond TNM, and to give advice
on methodology and validation. The subcommittee member-
ship as later revised is given in Table 1.
As of the London committee meeting in December of
2005, 100,869 lung cancer cases had been submitted to the
central database at CRAB from 45 sources in 20 countries
around the globe (Table 2). Of these, 81,495 are within the
time frame 1990–2000 and with sufficient staging and sur-
vival information to be included in the staging analysis (Table
3). There are data on 68,463 cases of non-small cell carci-
noma and 13,032 small cell cases. The contributing centers
can be categorized into registries, series (all cases treated by
a particular practitioner or group of practitioners), and clini-
cal trials, as shown in Table 4. Of these cases, 41% were
treated with surgery only, 11% with radiotherapy only, 23%
with chemotherapy only, and the rest with combined modal-
ities (Figure 1). The distribution by stage and geographic
region for included cases of small cell lung cancer and
non-small cell lung cancer are given in Figure 2. At this
meeting, the chairs of each subcommittee gave a presentation
of their initial deliberations. The whole committee discussed
these proposals and agreed on the further directions that
TABLE 1. Chairs and members of each subcommittee
T-descriptors Chairperson Ramon Rami-Porta
David Ball
John Crowley
Peter Goldstraw
James Jett
William Travis
Masahiro Tsuboi
Eric Vallieres
N-descriptors Chairperson Valerie Rusch
John Crowley
Jung-Gi Im
Peter Goldstraw
Ryosuke Tsuchiya
Johan Vansteenkiste
Prognostic factors Chairperson Jean-Paul Sculier
John Crowley
Peter Goldstraw
Thierry Le Chevalier
Jan van Meerbeeck
Small cell lung cancer Chairperson Frances A. Shepherd
Desmond Carney
John Crowley
Peter Goldstraw
Paul Van Houtte
Pieter E. Postmus
Validation and methodology Chairperson Patti Groome
John Crowley
Peter Goldstraw
Catherine Kennedy
Leslie Sobin
Mark Krasnik
M-descriptors Chairperson Pieter Postmus
Elizabeth Brambilla
John Crowley
Peter Goldstraw
Edward Patz
Hiroyasu Yokomise
Nodal chart Chairperson: Ryosuke Tsuchiya
David Ball
John Crowley
Peter Goldstraw
Edward Patz
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analyses should take. Each subcommittee met separately with
the Methodology and Validation subcommittee to ensure
uniform standards were established across the whole project.
The chairs of each subcommittee undertook development of
timelines that would be agreed with CRAB, allowing their
recommendations to be finalized by April of 2006. It was
accepted that evidence from sources outside of the database
should be included in these final recommendations to allow the
committee to present the UICC with comprehensive recommen-
dations for the next revision. Between April and the next
meeting in Seattle in June of 2006, the chairs of the subcom-
mittees, the chairman of the International Staging Committee,
and the CEO of CRAB will develop recommendations on
stage groupings based on further statistical analysis of the
new descriptors emanating from the subcommittees.
The final recommendations of the committee will be
agreed on at its meeting in June of 2006, submitted to the
Board of the IASLC in September, and transmitted to the
UICC by January of 2007. It has been agreed with the editor
of the Journal of Thoracic Oncology that the findings of each
subcommittee and the collected recommendations will be
disseminated throughout the lung cancer community through
a series of articles published in the Journal of Thoracic
Oncology during 2006–2007.
Once the International Staging Committee has com-
pleted this phase of its task, it will concentrate its activities
from June of 2006 on refining and expanding its findings in
the hope that these can be submitted to the American Joint
Committee on Cancer by mid 2007. This body has tradition-
ally forwarded its own recommendations directly to the UICC
but has cooperated in the past to ensure that a uniform system
emerges as the International System for Staging Lung Can-
TABLE 2. The number of cases submitted by each data
source, grouped by continent
Asia China 2007
Japan 7393
Korea 1119
Taiwan 1103
Total 11,622
Australia Prince Charles Hospital 1164
Peter MacCallum Cancer Centre 203
QRI 5472
St. Vincent’s Hospital 28
University of Sydney 1784
Western Hospital 765
Total 9416
Europe Amsterdam registry 14,869
Ankara 569
Belgrade 558
Faculty Hospital, Plzen 2006
ELCWP 2068
EORTC 2524
Flemish Registry 6303
GCCB-S 2993
Gdansk 1380
Grenoble 974
Heidelberg 5498
IALT 1867
IFCT 4015
IGR 398
Jules-Bordet 746
Leuven Lung Cancer Group 981
MRC CTU 4119
Norway Registry 2515
Perugia 111
Rotterdam Registry 2157
SLCG 557
Orbassano (Torino) 1259
Warsaw 234
Total 58,701
North America CALGB 3242
ECOG 3094
Johns Hopkins 1003
MDACC-RT 2099
MDACC-TCVS 521
MSKCC 1158
NCCTG 3293
NCIC CTG 1511
Princess Margaret Hospital 191
RTOG 2275
SWOG 2655
Wayne State University 88
Total 21,130
Global total No. of cases 100,869
TABLE 3. Numbers of cases submitted to the database
showing exclusions and the numbers remaining for analysis
Total cases submitted 100,869
Excluded from current analyses 19,374
Outside of 1990–2000 time frame 5467
Incomplete survival data 1192
Unknown histology 2419
Incomplete stage information 8075
Recurrent cases and other (e.g., not known if recurrent vs. newly
diagnosed, occult tumors)
1093
Carcinoids, sarcomas, other histologies 1128
Included in analyses 81,495
SCLC 13,032
NSCLC 68,463
SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer.
TABLE 4. The numbers of cases analyzed, listed by type of
data source
Registry 16,660
Series treated surgically 19,172
Clinical trial 24,239
Series treated by all modalities (including surgery) 7866
Consortium 5912
Institutional registry 5492
Surgical registry 2154
Total 81,495
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cer. The internal consultative process of the UICC should be
finalized before the end of 2008 and the revision enacted in
January of 2009.
This project has demonstrated the enthusiasm and will-
ingness of the lung cancer community, including partners in
industry, to cooperate and develop a more meaningful system
for lung cancer staging. We are grateful to those institutions
that collaborated in this project and are pleased to recognize
their important role in this effort. However, the committee
has already identified many aspects of the staging system that
FIGURE 1. Venn diagram showing the proportion
of submitted cases that received active treatment
by each modality.
FIGURE 2. (a) Histograms showing
the stage distribution of submitted
cases of non-small cell lung cancer
by continent. (b) Histograms show-
ing the stage distribution of submit-
ted cases of small cell lung cancer
by continent.
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can only be properly assessed in a prospective database. Most
centers understandably only collected data emphasized in
previous revisions. It is our intention to establish an expanded
data set that includes these previous data elements and new
prognostic factors regarded as candidates for improving the
staging system. We will publish this as a future publication in
the Journal of Thoracic Oncology so that those workers
intending to undertake prospective studies can include them
in their databases. We will seek funding to proceed with the
next phase of the project in which prospective data will be
collected for future revisions. We are confident that the lung
cancer community, recognizing the responsibility we all
share to do all that is possible to improve care for our patients
with lung cancer, will continue to support our efforts. We
welcome their involvement as stakeholders.
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IASCL INTERNATIONAL STAGING COMMITTEE
P. Goldstraw (Chairperson), Royal Brompton Hospital,
London, UK; D. Ball, Peter MacCallum Cancer Centre,
Melbourne, Australia; E. Brambilla, Laboratoire de Patholo-
gie Cellulaire, Grenoble Cedex, France; P. A. Bunn, Univer-
sity of Colorado Health Sciences, Denver, Colcorado; D.
Carney, Master Misericordiae Hospital, Dublin, Ireland; T.
Le Chevalier, Institut Gustave Roussy, Villejuif, France; J.
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ington; R. Ginsberg (deceased), Memorial Sloane Kettering
Cancer Centre, Chicago, Illinois; P. Groome, Queen’s Cancer
Research Institute, Kingston, Ontario, Canada; H. H. Hansen
(retired), National University Hospital, Copenhagen, Den-
mark; P. Van Houtte, Institute Jules Bordet, Bruxelles, Bel-
gium; J.-G. Im, Seoul National University Hospital, Seoul,
South Korea; J. R. Jett, Mayo Clinic, Rochester, Minnesota;
H. Kato (retired), Tokyo Medical Centre, Tokyo Japan; T.
Naruke (retired), Saiseikei Central Hospital, Tokyo, Japan;
E. F. Patz, Duke University Medical Centre, Durham, North
Carolina; P. E. Postmus, Free University Hospital, Amster-
dam, The Netherlands; R. Rami-Porta, Hospital Mutua de
Terrassa, Terrassa, Spain; V. Rusch, Memorial Sloane Ket-
tering Cancer Centre, Chicago, Illinois; J. P. Sculier, Institute
Jules Bordet, Bruxelles, Belgium; F. A. Shepherd, University
of Toronto, Toronto, Ontario, Canada. Y. Shimosato (retired),
Tokyo Medical College, Tokyo, Japan; L. Sobin, Armed
Forces Institute of Pathology, Washington, DC; W. Travis,
Memorial Sloan-Kettering Cancer Centre, Chicago, Illinois;
M. Tsuboi, Tokyo Medical Centre, Tokyo, Japan; R. Tsuchiya,
National Cancer Centre, Tokyo, Japan; E. Vallieres, Swedish
Cancer Institute, Seattle, Washington; Yoh Watanabe (de-
ceased), Kanazawa Medical University, Uchinada, Japan; and
H. Yokomise, Kagawa University, Kagawa, Japan.
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Seattle, Washington.
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Vansteenkiste, Leuven Lung Cancer Group, Belgium.
PARTICIPATING INSTITUTIONS
O. Visser, Amsterdam Cancer Registry, Amsterdam,
The Netherlands; R. Tsuchiya and T. Naruke, National Data
from Japan; J. P. Van Meerbeeck, Flemish Lung Cancer
Registry-VRGT, Brussels, Belgium; H. Bu¨lzebruck, Thorax-
klinik am Universitatsklinikum, Heidelberg, Germany; R.
Allison and L. Tripcony, Queensland Radium Institute,
Queensland, Australia; X. Wang, D. Watson, and J. Herndon,
Cancer and Leukemia Group B (CALGB), United States,
R. J. Stephens, Medical Research Council Clinical Trials
Unit, London, England; A. Depierre, E. Quoix, and Quan
Tran, Intergroupe Francophone de Cancerologie Thoracique
(IFCT), France; J. R. Jett and S. Mandrekar, North Central
Cancer Treatment Group (NCCTG), United States; J. H.
Schiller and R. J. Gray, Eastern Cooperative Oncology Group
(ECOG), United States; J. L. Duque-Medina and A. Lopez-
Encuentra, Bronchogenic Carcinoma Co-operative Group of
the Spanish Society of Pneumology and Thoracic Surgery
(GCCB-S), Spain; J. Crowley, Southwest Oncology Group
(SWOG), Bimodality Lung Oncology Team (BLOT), United
States; T. E. Strand, Cancer Registry of Norway; S. Swann
and H. Choy, Radiation Therapy Oncology Group (RTOG),
United States; R. Damhuis, Rotterdam Cancer Registry, The
Netherlands; R. Komaki and P. Allen, M. D. Anderson
Cancer Center (MDACC), United States; J. P. Sculier and M.
Paesmans, European Lung Cancer Working Party (ELCWP);
Y. L. Wu, Guangdong Provincial People’s Hospital, Peoples
Republic of China; M. Pesek and H. Krosnarova, Faculty
Hospital Plzen, Czech Republic; T. Le Chevalier and A.
Dunant, International Adjuvant Lung Cancer Trial (IALT),
France; B. McCaughan and C. Kennedy, University of Syd-
ney, Australia; F. Shepherd and M. Whitehead, National
Cancer Institute of Canada (NCIC); J. Jassem and W. Rzy-
man, Medical University of Gdansk, Poland; G. V. Scagliotti
and P. Borasio, Universita’ degli Studi di Torino, S. Luigi
Hospital, Orbassano, Italy; K. M Fong and L. Passmore,
Prince Charles Hospital, Australia; V. W. Rusch and K.
Meneses, Memorial Sloan-Kettering Cancer Center, United
States; H. J. Baek, Korea Cancer Centre Hospital, Seoul,
South Korea; R. P. Perng, Taiwan Lung Cancer Society,
Taiwan; R. C. Yung and A. Gramatikova, Johns Hopkins
University, United States; J. Vansteenkiste, Leuven Lung
Cancer Group (LLCG), Belgium; C. Brambilla and M. Col-
onna, Grenoble University Hospital-Isere Cancer Registry,
France; J. Hunt and A. Park, Western Hospital, Melbourne,
Australia; J. P. Sculier and T. Berghmans, Institute of Jules
Bordet, Brussels, Belgium; A. Kayi Cangir, Ankara Univer-
sity School of Medicine, Ankara, Turkey; D. Subotic, Clini-
cal Centre of Serbia, Belgrade, Serbia; R. Rosell and V.
Aberola, Spanish Lung Cancer Group (SLCG), Spain; A. A.
Vaporciyan and A. Correa, M. D. Anderson Cancer Center,
United States; J. P. Pignon, T. Le Chevalier, and R. Komaki,
Institut Gustave Roussy (IGR), France; T. Orlowski, Institute
of lung Diseases, Warsaw, Poland; D. Ball and P. Matthews,
Peter MacCallum Cancer Institute, Australia; M. Tsao, Prin-
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cess Margaret Hospital, Toronto, Ontario, Canada; S. Dar-
wish, Policlinic of Perugia, Italy; H. I. Pass and T. Stevens,
Karmanos Cancer Institute, Wayne State University, United
States; G. Wright, St. Vincent’s Hospital, Victoria, Australia;
and C. Legrand and J. P. van Meerbeeck, European Organi-
sation for Research and Treatment of Cancer (EORTC),
Brussels, Belgium.
APPENDIX 2
SUMMARY OF DATA ELEMENTS
Name of database
Type of database
Protocol number if applicable
PATIENT CHARACTERISTICS
Date of birth
Gender
Smoking history
Weight loss history
Performance status
Prior treatment
DISEASE DESCRIPTION
Date of diagnosis or trial entry, if applicable
Type of disease: new versus recurrent
Diagnosis by cytology or histology, method of diagno-
sis
Histologic type (World Health Organization, 3rd Edi-
tion)
Size of primary tumor (radiologic)
Location of primary tumor
Presence of pleural effusion, pleural effusion cytology
Laboratory values
TNM STAGE (UICC VERSION 6)
Clinical T-stage
Method of clinical T-stage determination
Specification of cT-descriptors (UICC Version 6)
Clinical N-stage
Method of clinical N-stage determination
Clinical M-stage
Method of M-stage determination
Location of metastatic sites
Pathologic T-stage (pT or ypT)
Size of primary tumor (pathologic)
Specification of pT-descriptors
Pathologic N-stage
Nodal stations examined and status of each station
Pathological M-stage
Location of metastatic sites, pathologic (if different
from clinical)
Stage of disease, extensive versus limited for small cell
lung cancer
TREATMENT
Lung surgery, yes/no
Date of surgery
Approach to resection
Extent of resection
Additional components of resection
Completeness of resection (R0, R1, R2)
Radiation therapy, yes/no
Sites of radiation therapy
Dates of radiation therapy
Radiation therapy intent and schema
Chemotherapy, yes/no
Type of chemotherapy
Dates of chemotherapy
OUTCOME
Date of last follow-up/death
Status at last follow-up
Date of progression
Site and location of progression
Cause of death
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